GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (LTS:0IV3) » Definitions » EV-to-EBIT

Geron (LTS:0IV3) EV-to-EBIT : -11.42 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Geron EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Geron's Enterprise Value is $2,159.45 Mil. Geron's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-189.07 Mil. Therefore, Geron's EV-to-EBIT for today is -11.42.

The historical rank and industry rank for Geron's EV-to-EBIT or its related term are showing as below:

LTS:0IV3' s EV-to-EBIT Range Over the Past 10 Years
Min: -2044.86   Med: -5.66   Max: 5049.58
Current: -11.42

During the past 13 years, the highest EV-to-EBIT of Geron was 5049.58. The lowest was -2044.86. And the median was -5.66.

LTS:0IV3's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 9.9 vs LTS:0IV3: -11.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Geron's Enterprise Value for the quarter that ended in Sep. 2024 was $2,479.54 Mil. Geron's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-189.07 Mil. Geron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -7.63%.


Geron EV-to-EBIT Historical Data

The historical data trend for Geron's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron EV-to-EBIT Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.97 -4.37 -2.37 -6.13 -5.13

Geron Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.35 -5.13 -8.32 -10.91 -13.15

Competitive Comparison of Geron's EV-to-EBIT

For the Biotechnology subindustry, Geron's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Geron's EV-to-EBIT falls into.



Geron EV-to-EBIT Calculation

Geron's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2159.448/-189.074
=-11.42

Geron's current Enterprise Value is $2,159.45 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-189.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron  (LTS:0IV3) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Geron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=-189.074/2479.54106
=-7.63 %

Geron's Enterprise Value for the quarter that ended in Sep. 2024 was $2,479.54 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-189.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Geron's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron Headlines

No Headlines